Core Viewpoint - The stock of Vanguard Medical Biotechnology (00399) experienced a significant decline of 7.69%, trading at HKD 0.42 per share with a transaction volume of HKD 5.9847 million as of 10:26 AM on August 21 [1] Company Overview - Vanguard Medical Biotechnology focuses on the research and development of oral insulin products, as well as the trade of beauty instruments and products [1] - The company is committed to acquiring commercially viable pharmaceutical products and was formerly known as United Gene Technology Group [1] - It is currently listed on the main board of the Hong Kong Stock Exchange under stock code 399 [1] Financial Performance - As of the 2024 annual report, Vanguard Medical Biotechnology reported total revenue of HKD 1.9296 million and a net loss of HKD 319 million [2]
领航医药生物科技(00399)下跌7.69%，报0.42元/股